- Recent Funding
- Investors
- Abingworth
Abingworth portfolio
Abingworth has 6 portfolio companies on record at Recent Funding, with 3 investments in the last 12 months.
About this page
It is a venture capital firm based in London, GB, founded in 1987. It led 6 of the 8 rounds it joined. Its most recent investment on record is AdvanCell's $315M Series B+ round in July 2026, alongside Fidelity Management & Research Company, Morningside, Eli Lilly and 15 others. By category, its portfolio leans toward Health and bio (6) and Manufacturing and industrial (1). It has co-invested with Sanofi Ventures, SymBiosis and Brandon Capital, most often Sanofi Ventures (4 rounds).
About Abingworth
What Abingworth invests in
- Health and bio · 6 · 100%
- Manufacturing and industrial · 1 · 17%
Abingworth recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| Series B+ · $315M | Fidelity Management & Research Company, Morningside, Eli Lilly +15 | ||
| Series A · $77.5M · lead | DaVita Venture Group (lead), U.S. Renal Care, SymBiosis +2 | ||
| Series A · $100M · lead | OUP, Bill & Melinda Gates Foundation, SR One (lead) +2 | ||
| Series B+ · $115M | Advent Life Sciences (lead), RiverVest, Novo Holdings +6 | ||
| Series B+ · $112M · lead | Morningside, SymBiosis (lead), Brandon Capital +3 | ||
| Series A · $120M · lead | Cancer Research Horizons, Novo Holdings (lead), Eli Lilly +3 | ||
| Series B+ · $68M · lead | RiverVest, Novo Holdings, Sanderling Ventures +5 | ||
| Series B+ · $46.94M · lead | LSP BioVentures, 5AM Ventures, Versant Ventures |
How Abingworth invests
Abingworth portfolio companies
AAdvanCell$315MSeries B+ · Jul 2026
RR1 Therapeutics$77.5MSeries A · Mar 2026
AAddition Therapeutics$100MSeries A · Dec 2025
GGlycomine$115MSeries B+ · May 2025
MMyricx Bio$120MSeries A · Jul 2024
NNouscom$46.94MSeries B+ · Jun 2017
| Company | Round with Abingworth | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series B+ · $315M | $439.5M | Jul 15, 2026 Series B+ |
Health and bio |
Series A · $77.5M · lead | $158M | Sep 30, 2026 Series A |
Health and bio |
Series A · $100M · lead | $100M | Dec 17, 2025 Series A |
Health and bio |
Series B+ · $115M | $195M | May 9, 2025 Series B+ |
Health and bio |
Series A · $120M · lead | $120M | Jul 8, 2024 Series A |
Health and bio |
Series B+ · $46.94M · lead | $267.56M | Oct 19, 2026 Series B+ |
Most frequent co-investors
SSanofi Ventures4 shared rounds · last Jul 15, 2026
SSymBiosis3 shared rounds · last Jul 15, 2026
BBrandon Capital3 shared rounds · last Jul 15, 2026
NNovo Holdings3 shared rounds · last May 9, 2025
EEli Lilly2 shared rounds · last Jul 15, 2026
MMorningside2 shared rounds · last Jul 15, 2026
TTenmile2 shared rounds · last Jul 15, 2026
SSV Health Investors2 shared rounds · last Jul 15, 2026
SSanderling Ventures2 shared rounds · last May 9, 2025
CChiesi Ventures2 shared rounds · last May 9, 2025
RRiverVest2 shared rounds · last May 9, 2025
RRemiges Ventures2 shared rounds · last May 9, 2025
Similar investors
AAdage Capital Management6 companies · 4 deals in 12 mo
HHealthier Capital6 companies · 4 deals in 12 mo
UUC Investments6 companies · 4 deals in 12 moHHBM Healthcare Investments6 companies · 3 deals in 12 mo
TThe FSE Group6 companies · 3 deals in 12 mo
TThird Rock Ventures6 companies · 2 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.
Share is of the 8 rounds on Recent Funding that name Abingworth. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Abingworth, which is a subset of its real portfolio. API: /api/v1/investors/abingworth (get a free API key). More: the most active VC firms and new venture capital funds.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy